Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Alejandro Javier Yovine"'
Autor:
Yi-Long Wu, Ji-Youn Han, Terufumi Kato, Fabrice Barlesi, Edward B. Garon, Federico Cappuzzo, Yuji Shibata, Nathalie Smith, Sadhvi Khanna, Riccardo Belli, Alejandro Javier Yovine, Daniel S.W. Tan
Publikováno v:
Journal of Clinical Oncology. 40:TPS9153-TPS9153
TPS9153 Background: MET amplification can arise as a bypass resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs) and occurs in ̃5-26% of EGFR TKI resistant EGFR-mutant non-small cell lung cancer (NSCLC). These patients (pts) have limited t
Autor:
Lorin Roskos, Alejandro Javier Yovine, Rosalinda Hgp Arends, Nassim Morsli, Ignacio González-García, Xiang Guo, James Xie, Paul Baverel
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
The potential for durvalumab, a programmed cell death ligand-1 (PD-L1)-blocking monoclonal antibody, to treat head and neck squamous cell carcinoma (HNSCC) is being evaluated in multiple clinical trials. We assessed circulating proteins at baseline t
Autor:
Tze Heng Tan, Maria Libera Ascierto, Emma V. Jones, Sophie E. Willis, Amelia Raymond, Dimitris Polychronopoulos, Alejandro Javier Yovine, Nassim Morsli, Carl Barrett, Sriram Sridhar, Helen K. Angell, Patricia McCoon
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Head and neck squamous cell carcinoma (HNSCC) is composed of a heterogeneous group of tumors arising trough environmental carcinogens or infection by human papillomavirus (HPV). Treatment interventions such as immunotherapy and targeted th
Autor:
Ricard Mesia, Paul Scorer, Todd Hembrough, Philip He, Weimin Li, Jill Walker, Jiabu Ye, Nicholas Holoweckyj, Alejandro Javier Yovine, Robert I. Haddad, Qu Zhang, Lisa Licitra, Rajiv Raja, J. Shetty, Han Si, Robert L. Ferris, Sophie Wildsmith, Nassim Morsli, Katia Real
Publikováno v:
Journal of Clinical Oncology. 38:6511-6511
6511 Background: In NSCLC, bTMB assessed from circulating tumor DNA shows promise as a predictive survival biomarker for immunotherapy, but its value in R/M HNSCC is uncertain. We evaluated bTMB as a predictor of survival in R/M HNSCC. Methods: EAGLE
Autor:
Vadryn Pierre, Alejandro Javier Yovine, Paul Baverel, Weimin Li, Lorin Roskos, Nassim Morsli, Ignacio González-García, Rajesh Narwal, Xiang Guo
Publikováno v:
Journal of Clinical Oncology. 38:6549-6549
6549 Background: Optimal patient selection for immunotherapy remains a challenge as most patients fail to respond. We aim to assess baseline factors for association with long-term survival from durvalumab treatment in patients with recurrent/metastat
Autor:
Paul Baverel, Brandon W. Higgs, Alejandro Javier Yovine, Jean Fan, Nassim Morsli, Shao-Chun Chang, Lorin Roskos, Rosalin Arends, Magdalena Wrona, Xiang Guo
Publikováno v:
Journal of Clinical Oncology. 37:6048-6048
6048 Background: The potential for durvalumab, a PD-L1 blocking monoclonal antibody, to treat head and neck squamous cell carcinoma (HNSCC) is being evaluated in multiple clinical trials. We assessed circulating protein biomarkers in HNSCC patients p